Aradigm Corporation

Aradigm Corporation

Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

Contact Details

Office Address

Aradigm Corporation
3929 Point Eden Way
Hayward, CA, USA 94545
Phone: (510) 265-9000
Fax: (510) 265-0277

Executives

Chief Exec. Officer, Pres and Exec. Director

Dr. Igor Gonda

Chief Financial Officer

Ms. Nancy E. Pecota

Business Reviews for Aradigm Corporation

Related Companies